With ParexelAI™, you're not just optimizing your current development timeline, you're unlocking the ability to run more programs simultaneously across our global network and compress critical timelines. In a landscape where speed to market directly impacts patient outcomes, ParexelAI empowers you to innovate and make a meaningful difference in patients' lives.

Read press release

Faster delivery that's reliable

ParexelAI represents a transformative opportunity for companies seeking to accelerate their path to patients. This innovative, proprietary suite of AI services and capabilities fundamentally reimagines clinical development by combining our operational excellence with cutting-edge AI technology. By partnering with Parexel, you gain access to a fully AI-enabled clinical development partner that delivers greater speed, quality, and efficiency. 


How ParexelAI is driving value

%
reduction in site selection process timelines
%
reduction in clinical study report preparation
%
efficiency gains in safety literature review and case processing​

Supported by strategic partnerships

  • Through its strategic partnership with Paradigm Health, Parexel is transforming patient identification and trial access across a network of 800+ research sites and 2,100+ provider locations. 
  • Working with Weave Bio, Parexel is reducing Investigational New Drug (IND) and New Drug Application (NDA) authoring timelines by 60% through regulatory automation, helping sponsors reach high-stakes regulatory decisions sooner than previously possible. 
  • Parexel was the first CRO to adopt Palantir’s Artificial Intelligence Platform, which serves as the backbone for its AI-enabled clinical operations, supporting faster, higher-quality study delivery. 
  • Parexel also leverages partnerships with other leading technology companies to access the latest innovations and provide its customers with a truly AI-enabled clinical development partner.  
     

Case Study 1 of 4

Transforming clinical research associate productivity with citizen developers

To improve delivery speed and support the “safe to proceed” path for sponsors, Clinical Research Associate (CRA) teams needed streamlined, automated workflows.

Situation

To improve delivery speed and support the “safe to proceed” path for sponsors, Clinical Research Associate (CRA) teams needed streamlined, automated workflows.

Advantages

Untitled design (3).jpg


Trusted expertise

Risk managed, compliance assured — human-led AI combines regulatory rigor with intelligent automation to drive operational excellence and protect data integrity.


Empowered workforce

AI solutions elevate experts to focus on problem-solving and higher-impact challenges to
deliver solutions others don’t see.


Unlocked insights

Drive smarter decisions and faster trials — AI surfaces predictive insights at every stage, reducing protocol risk, study delays, and costly trial amendments.


High-performance delivery

Consistent operational excellence, delivered at speed — end-to-end AI eliminates rework and manual bottlenecks to accelerate site activation, enrollment, data analysis and submission timelines.


Best-in-class collaborations

An intentional partner strategy with best of breed providers unites domain expertise with access to leading AI platforms for solutions that drive innovation, reach new patients and deliver speed with precision.

AI drives speed without shortcuts across the clinical trial lifecycle

  • Study design optimizer
    Impact: Informs fit-for-purpose protocol design through rapid analysis of similar public protocols​

  • Protocol abstraction
    Impact: Expedites insight identification for protocol design from past Parexel protocols

  • Study companion
    Impact: Analyzes historical data from past Parexel projects to optimize early feasibility

  • Patient recruitment​
    Impact: Speeds patient recruitment & time to first patient in (Paradigm Health)​

  • Patient motivation assessment​
    Impact: Identifies patients and measures motivation to inform protocol design impact and patient engagement strategies

  • Site feasibility​
    Impact: Rapid data analysis across global site networks enables fast site identification based on protocol requirements​

  • Contract Automation​
    Impact: Uses historical data to automate draft generation and reduce site contracting timelines​

     

  • Regulatory compliance
    Impact: Enables proactive compliance by automating Clinical Trials Information System (CTIS) monitoring

  • Study Data Tabulation Model (SDTM) Generation​
    Impact: Automates creation of SDTM datasets, disparate data integration and streamlines data workflows

  • Safety processing
    Impact: Automates safety literature review, enabling earlier signal detection

  • Safety Individual Case Safety Report (ICSR) Intake​
    Impact: Accelerates delivery timelines for individual Clinical Study Reports (CSRs)

  • Resource management​
    Impact: Enables precision resourcing for full-service outsourcing and functional service provider delivery models

  • R Biostatistical Platform​
    Impact: Automates R workflows to ensure regulatory-ready analytics

  • Statistical Analysis System (SAS) Code Reviewer​
    Impact: Drives faster quality review of SAS coding

  • Clinical Study Report (CSR) Generation​
    Impact: Generates quality control for CSR draft, resulting in 30% CSR timeline reduction​

How we're different

Our customers gain an “insight advantage” in navigating AI regulatory requirements across global markets.

AI will never replace our domain expertise. Every AI solution requires human decision-making and is assistive by design.

End-to-end coverage – Solutions across the entire trial lifecycle.


Our latest insights

Blog

Regulatory submissions as a source of insight: How AI can amplify the value of our work

Jul 15, 2026

CTB Blog

Modeling & simulation and artificial intelligence for early drug development

Jul 14, 2026

Blog

Human-centered AI - A dual-layer model for clinical research excellence

Jul 1, 2026

Blog

The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem

Jul 1, 2026

CTB Blog

Modernizing data operations to enable today's Phase 1 trials

Jul 1, 2026

Whitepaper

AI-powered pharmacovigilance: From reactive reporting to predictive risk

Mar 24, 2025

Podcast

Enabling Successful Sites: Episode 4, Part Two: Leveraging AI to improve patient recruitment and retention

Jan 6, 2025

Whitepaper

Harnessing the Benefits of Externally Controlled Clinical Trials (ECTs) to Accelerate Development of Better Medicines

Nov 25, 2024

Article

Human-in-the loop AI: a proven approach to streamlining PV case processing and review

Oct 7, 2024

Blog

Transforming evidence generation: How predictive AI can optimize clinical development

Sep 3, 2024

Blog

The future of drug development: Leveraging EMA support for use of alternative nonclinical approaches

Jun 6, 2024

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Article

Parexel principles for artificial intelligence (AI)

Mar 6, 2024

Blog

Using ethical AI to streamline HEOR

Jan 26, 2024

Video

Insights with Goldman Sachs Part 5: Pioneering new approaches, technologies, and AI to drive innovation

Jan 26, 2024

Our latest insights

Blog

Regulatory submissions as a source of insight: How AI can amplify the value of our work

Jul 15, 2026

CTB Blog

Modeling & simulation and artificial intelligence for early drug development

Jul 14, 2026

Blog

Human-centered AI - A dual-layer model for clinical research excellence

Jul 1, 2026

Blog

The connected submission - How AI, automation, and intelligence are changing the regulatory ecosystem

Jul 1, 2026

CTB Blog

Modernizing data operations to enable today's Phase 1 trials

Jul 1, 2026

Whitepaper

AI-powered pharmacovigilance: From reactive reporting to predictive risk

Mar 24, 2025

Show more